DCT

1:23-cv-03937

Currax Pharma LLC v. Ajanta Pharma Ltd

Log In

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:23-cv-03937, D.N.J., 07/24/2023
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey primarily because Defendant Ajanta Pharma USA Inc. is a corporation incorporated in the state of New Jersey.
  • Core Dispute: Plaintiff alleges that Defendants' proposed generic 3 mg and 6 mg doxepin hydrochloride tablets, for which Abbreviated New Drug Application (ANDA) No. 218564 was filed, will infringe ten U.S. patents related to methods of using low-dose doxepin for the treatment of insomnia.
  • Technical Context: The technology concerns specific methods of using low-dose doxepin, a tricyclic antidepressant, to treat insomnia, particularly difficulties with sleep maintenance, early awakenings, and fragmented sleep.
  • Key Procedural History: This action was initiated under the Hatch-Waxman Act following a notice letter dated June 12, 2023, in which Ajanta informed Currax that it had filed an ANDA with a Paragraph IV certification seeking FDA approval to market a generic version of Currax's SILENOR® product prior to the expiration of the ten patents-in-suit.

Case Timeline

Date Event
2006-05-19 Earliest Priority Date for ’299, ’898, ’437, ’607, ’620, ’662 Patents
2006-07-24 Earliest Priority Date for ’307, ’814, ’660, ’074 Patents
2010-03-17 FDA Approval of SILENOR® New Drug Application
2011-03-29 U.S. Patent No. 7,915,307 Issues
2013-08-20 U.S. Patent No. 8,513,299 Issues
2015-08-18 U.S. Patent No. 9,107,898 Issues
2016-11-08 U.S. Patent No. 9,486,437 Issues
2017-02-21 U.S. Patent No. 9,572,814 Issues
2018-01-09 U.S. Patent No. 9,861,607 Issues
2019-03-26 U.S. Patent No. 10,238,620 Issues
2020-05-19 U.S. Patent No. 10,653,660 Issues
2020-05-19 U.S. Patent No. 10,653,662 Issues
2021-09-07 U.S. Patent No. 11,110,074 Issues
2023-06-12 Ajanta sends Notice Letter to Currax regarding ANDA filing
2023-07-24 Complaint for Patent Infringement Filed

II. Technology and Patent(s)-in-Suit Analysis

No probative visual evidence provided in complaint.

U.S. Patent No. 7,915,307 - "Methods of Improving the Pharmacokinetics of Doxepin," issued March 29, 2011

The Invention Explained

  • Problem Addressed: The patent describes the "food effect" as an unpredictable phenomenon that can influence the absorption of drugs, affecting the time to reach maximum concentration (Tmax) and the overall bioavailability (AUC) (’307 Patent, col. 1:25-41). For sleep medications like doxepin, this variability is problematic, as a rapid onset and predictable duration are therapeutically desirable (’307 Patent, col. 1:49-52).
  • The Patented Solution: The invention is a method of administering doxepin that controls for the food effect to achieve a specific therapeutic outcome. It claims that administering doxepin without food, or specifically at least three hours after a meal, shortens the time to achieve maximum plasma concentration, resulting in a more rapid onset of drug action (’307 Patent, col. 2:21-34). This method is intended to provide a faster onset of sleep therapy and reduce next-day residual effects (Compl. ¶44).
  • Technical Importance: The invention provides a specific dosing regimen to optimize the pharmacokinetic profile of a known drug for a new use (sleep therapy), thereby improving efficacy and potentially reducing side effects (’307 Patent, col. 2:16-20).

Key Claims at a Glance

  • The complaint asserts at least Claim 1 (Compl. ¶44).
  • The essential elements of independent Claim 1 are:
    • A method for providing sleep therapy comprising administering a 3 mg or a 6 mg dose of doxepin to an individual
    • at least three hours after consuming a meal,
    • thereby providing a faster onset of action and reducing next day residual effects.
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent.

U.S. Patent No. 8,513,299 - "Methods of Using Low-Dose Doxepin for the Improvement of Sleep," issued August 20, 2013

The Invention Explained

  • Problem Addressed: The patent background identifies two common problems in treating insomnia: 1) "early termination of sleep or premature final awakening," and 2) the "serious hangover effects" caused by drugs powerful enough to induce a full eight hours of sleep (’299 Patent, col. 1:50-61).
  • The Patented Solution: The invention is a method for treating patients who specifically suffer from premature final awakenings. The method involves identifying a patient whose sleep terminates in the last 60 minutes of a desired 8-hour sleep period and then providing a low dose of doxepin (between 0.5 and 6 mg) to lengthen the sleep period, purportedly without causing "untoward side effects" (’299 Patent, col. 2:25-40).
  • Technical Importance: This approach tailors the use of low-dose doxepin to a specific sub-population of insomnia patients—those with early awakenings—aiming to improve sleep maintenance in the final hours of the night without causing next-day impairment.

Key Claims at a Glance

  • The complaint asserts at least Claim 1 (Compl. ¶49).
  • The essential elements of independent Claim 1 are:
    • A method for reducing or preventing early awakenings in a patient in need thereof, comprising:
    • identifying a patient having a sleep disorder in which, for a given 8 hour period of desired sleep, the patient experiences a sleep period that terminates during the final 60 minutes of said period; and
    • providing to the patient doxepin or a pharmaceutically acceptable salt thereof in a dosage between about 0.5 and 6 mg that is effective to lengthen the sleep period.
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent.

U.S. Patent No. 9,107,898 - "Methods of Using Low-Dose Doxepin for the Improvement of Sleep," issued August 18, 2015

  • Technology Synopsis: This patent claims a method for treating sleep maintenance insomnia in elderly patients characterized by fragmented sleep, particularly during the final hour of an 8-hour sleep period. The solution involves identifying such a patient and administering a low dose of doxepin (3 to 6 mg) to reduce fragmented sleep (’898 Patent, col. 2:54-66).
  • Asserted Claims: At least Claim 1 (Compl. ¶54).
  • Accused Features: Ajanta's ANDA Products are accused of infringing through their intended use for treating sleep maintenance insomnia, which will allegedly be encouraged by product instructions (Compl. ¶55).

U.S. Patent No. 9,486,437 - "Methods of Using Low-Dose Doxepin for the Improvement of Sleep," issued November 8, 2016

  • Technology Synopsis: The patent claims a method for treating sleep maintenance insomnia characterized by fragmented sleep during the 8th hour of sleep. The method comprises administering a low dosage of doxepin (0.5 to 6 mg) to a patient who experiences fragmented sleep during the final 60 minutes of an 8-hour sleep period (’437 Patent, col. 2:51-60).
  • Asserted Claims: At least Claim 1 (Compl. ¶59).
  • Accused Features: The intended use of Ajanta's ANDA Products for insomnia, allegedly induced by accompanying instructions, is accused of infringing (Compl. ¶60).

U.S. Patent No. 9,572,814 - "Methods of Improving the Pharmacokinetics of Doxepin," issued February 21, 2017

  • Technology Synopsis: This patent is directed to a method of treating insomnia by administering doxepin (0.5 to 7 mg) at least three hours after a meal. This timing regimen is claimed to provide a faster onset of action and reduce next-day residual effects, similar to the ’307 Patent (’814 Patent, col. 2:48-58).
  • Asserted Claims: At least Claim 1 (Compl. ¶64).
  • Accused Features: Infringement is alleged based on the anticipated instructions for Ajanta's ANDA products, which are expected to encourage administration in the claimed manner (Compl. ¶65).

U.S. Patent No. 9,861,607 - "Methods of Using Low-Dose Doxepin for the Improvement of Sleep," issued January 9, 2018

  • Technology Synopsis: The patent describes a method for treating insomnia characterized by difficulties with sleep maintenance. The method involves administering a low dose of doxepin (1 to 6 mg) to a patient experiencing fragmented sleep during the final 60 minutes of a desired 8-hour sleep period (’607 Patent, col. 2:50-59).
  • Asserted Claims: At least Claim 1 (Compl. ¶69).
  • Accused Features: Ajanta's ANDA Products are accused of infringing based on their intended use for insomnia, which will allegedly be promoted via product instructions (Compl. ¶70).

U.S. Patent No. 10,238,620 - "Methods of Using Low-Dose Doxepin for the Improvement of Sleep," issued March 26, 2019

  • Technology Synopsis: The patent claims a method for treating insomnia by administering an oral formulation of doxepin (1 to 7 mg) prior to bedtime to a patient who experiences fragmented sleep during the final 60 minutes of a desired 8-hour sleep period (’620 Patent, Abstract; col. 1:55-65).
  • Asserted Claims: At least Claim 1 (Compl. ¶74).
  • Accused Features: The intended use of Ajanta's oral tablets for treating insomnia, as allegedly directed by product labeling, is accused of infringing (Compl. ¶75).

U.S. Patent No. 10,653,660 - "Methods of Improving the Pharmacokinetics of Doxepin," issued May 19, 2020

  • Technology Synopsis: This patent is directed to a method of treating insomnia by administering doxepin (0.5 to 7 mg) at least 3 hours after a meal. Similar to the ’307 and ’814 patents, this method is claimed to provide a faster onset of action and minimize next-day sedation (’660 Patent, col. 2:50-58).
  • Asserted Claims: At least Claim 1 (Compl. ¶79).
  • Accused Features: Infringement is alleged on the basis that Ajanta's product instructions will induce users to administer the drug according to the claimed method (Compl. ¶80).

U.S. Patent No. 10,653,662 - "Methods of Using Low-Dose Doxepin for the Improvement of Sleep," issued May 19, 2020

  • Technology Synopsis: The patent claims a method of treating insomnia by administering an oral formulation of doxepin (1 to 7 mg) prior to bedtime to a patient having difficulty staying asleep during the final 60 minutes of a desired 8-hour sleep period (’662 Patent, Abstract; col. 2:50-59).
  • Asserted Claims: At least Claim 1 (Compl. ¶84).
  • Accused Features: Ajanta's ANDA Products are accused of infringing through their intended use as an oral formulation for insomnia, allegedly encouraged by product instructions (Compl. ¶85).

U.S. Patent No. 11,110,074 - "Methods of Improving the Pharmacokinetics of Doxepin," issued September 7, 2021

  • Technology Synopsis: This patent claims a method of treating insomnia by administering doxepin (0.5 to 7 mg) at least 3 hours after a meal to provide faster onset of action. This patent is in the same family as the ’307, ’814, and ’660 patents and claims a similar method (’074 Patent, col. 2:50-56).
  • Asserted Claims: At least Claim 1 (Compl. ¶89).
  • Accused Features: The complaint alleges that the instructions accompanying Ajanta's ANDA products will induce infringement of the claimed method (Compl. ¶90).

III. The Accused Instrumentality

Product Identification

  • The accused products are Ajanta's 3 mg and 6 mg doxepin hydrochloride oral tablets (“Ajanta’s ANDA Products”), for which Ajanta filed ANDA No. 218564 with the FDA (Compl. ¶10).

Functionality and Market Context

  • The complaint alleges that Ajanta's ANDA Products, if approved, will have the same active ingredient, method of administration, dosage form, and strength as Currax's SILENOR® tablets and will be bioequivalent (Compl. ¶37). The products are intended to be indicated for the treatment of insomnia characterized by difficulties with sleep maintenance (Compl. ¶38). Ajanta's filing of an ANDA represents a commercial effort to market a generic version of SILENOR® (Compl. ¶34).

IV. Analysis of Infringement Allegations

U.S. Patent No. 7,915,307 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for providing sleep therapy comprising administering a 3 mg or a 6 mg dose of doxepin to an individual... Ajanta's ANDA Products are 3 mg and 6 mg doses of doxepin hydrochloride intended for sleep therapy. ¶10, ¶38 col. 15:61-63
...at least three hours after consuming a meal... Ajanta will allegedly provide instructions that encourage, recommend, or promote taking the product at least three hours after a meal. ¶45 col. 15:64
...thereby providing a faster onset of action and reducing next day residual effects. The complaint alleges infringement of the method claim as a whole through inducement, implying the intended use will achieve the claimed result. ¶44-45 col. 15:65-67
  • Identified Points of Contention:
    • Scope Questions: The complaint's infringement theory rests on inducement, alleging that Ajanta's product instructions will direct users to perform the claimed method. A central question will be whether the specific language of Ajanta's proposed label and other instructional materials will meet the "at least three hours after consuming a meal" limitation, or if the instructions will be more general (e.g., "take on an empty stomach"), raising a dispute over whether such language is sufficient to encourage infringement.
    • Technical Questions: What evidence does the complaint provide regarding the specific content of the instructions that will allegedly accompany Ajanta’s ANDA Products? The infringement allegation is prospective and depends entirely on the content of materials that will be distributed if the ANDA is approved.

U.S. Patent No. 8,513,299 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for reducing or preventing early awakenings in a patient in need thereof, comprising: identifying a patient having a sleep disorder in which, for a given 8 hour period of desired sleep, the patient experiences a sleep period that terminates during the final 60 minutes of said period;... Ajanta's ANDA is for a product indicated for insomnia with sleep maintenance difficulties. The complaint alleges Ajanta's instructions will induce physicians to identify and prescribe to patients with this specific disorder. ¶38, ¶50 col. 37:48-55
...and providing to the patient doxepin or a pharmaceutically acceptable salt thereof in a dosage between about 0.5 and 6 mg that is effective to lengthen the sleep period. Ajanta's ANDA Products are 3 mg and 6 mg doses of doxepin, which fall within the claimed dosage range and are intended to treat sleep maintenance issues. ¶10, ¶37-38 col. 37:56-59
  • Identified Points of Contention:
    • Scope Questions: Claim 1 includes a specific diagnostic step: "identifying a patient" who experiences sleep termination "during the final 60 minutes" of the sleep period. A key question for the court may be whether seeking FDA approval for a general sleep maintenance insomnia indication is sufficient to induce infringement of this specific diagnostic step, or if more direct evidence of encouragement is required.
    • Technical Questions: Does the act of marketing a bioequivalent generic drug for the same indication as the branded product (SILENOR®) inherently induce physicians and patients to perform all method steps claimed in the patents covering that branded product's use? The analysis will likely focus on whether Ajanta takes affirmative steps to instruct or encourage the specific "identifying" limitation of the claim.

V. Key Claim Terms for Construction

The Term: "identifying a patient having a sleep disorder in which... the patient experiences a sleep period that terminates during the final 60 minutes of said period" (’299 Patent, Claim 1)

  • Context and Importance: This diagnostic step is a critical limitation in several of the asserted patents. Practitioners may focus on this term because its construction will determine the evidence required to prove inducement. The dispute will likely center on whether a general diagnosis of "sleep maintenance insomnia" meets this limitation, or if a more specific finding based on polysomnography or detailed patient reporting is required.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent's background describes "sleep maintenance difficulty" as the most commonly reported symptom in primary care patients, suggesting the invention is directed to a common clinical presentation rather than a narrow, test-defined condition (’299 Patent, col. 1:41-45).
    • Evidence for a Narrower Interpretation: The claim language itself is highly specific ("final 60 minutes"). The detailed description of clinical trials used to support the patent likely outlines specific, objective criteria (e.g., from polysomnography) used to "identify" qualifying patients, which could be argued to limit the claim's scope (’299 Patent, Example 18-21).

The Term: "at least three hours after consuming a meal" (’307 Patent, Claim 1)

  • Context and Importance: This behavioral limitation is the core of the ’307 patent and related patents in the family. Its definition is critical because infringement will depend on what Ajanta's product label instructs users to do. The dispute will be whether a general instruction like "take on an empty stomach" is equivalent to the specific "at least three hours" limitation.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The patent discusses the invention in the context of avoiding the "food effect," a general principle in pharmacology often addressed by "empty stomach" instructions (’307 Patent, col. 1:25-41).
    • Evidence for a Narrower Interpretation: The patent specification explicitly links the "three hours" timing to achieving a faster Tmax, tying the claim language directly to the pharmacokinetic discoveries disclosed (’307 Patent, col. 2:1-4). The claim itself recites the functional result of this timing ("thereby providing a faster onset of action"), suggesting the timing is not arbitrary and is a specific solution to the stated problem.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement for all ten patents. The core factual basis is the allegation that Ajanta will "knowingly provide Ajanta's ANDA Products with instructions for administering those products in a manner that directly infringes," and that physicians and/or patients who follow those instructions will be direct infringers (Compl. ¶45, ¶50, ¶55, ¶60, ¶65, ¶70, ¶75, ¶80, ¶85, ¶90).
  • Willful Infringement: The complaint alleges that Ajanta was aware of the patents-in-suit when it filed its ANDA (Compl. ¶36). Pre-suit knowledge is explicitly alleged based on Ajanta's June 12, 2023 "Notice Letter," which informed Currax of the ANDA filing and its Paragraph IV certification against the asserted patents (Compl. ¶35). The filing of the lawsuit itself establishes post-notice knowledge for any continuing conduct.

VII. Analyst’s Conclusion: Key Questions for the Case

  • A core issue will be one of induced infringement and label scope: As this is a prospective Hatch-Waxman action, the case will likely turn on the specific language of Ajanta's proposed product labeling. A key question for the court will be whether the instructions on that label actively encourage or recommend the specific diagnostic and behavioral steps required by the asserted method claims, or if the language is sufficiently general to avoid inducement.
  • A second central issue will be one of claim construction: Can the diagnostic step of "identifying a patient" who awakens in the "final 60 minutes" of sleep be satisfied by a general clinical diagnosis of sleep maintenance insomnia? Similarly, can the behavioral step of administering the drug "at least three hours after consuming a meal" be met by a generic "take on an empty stomach" instruction? The answers to these definitional questions will determine the scope of the patents and the strength of the infringement allegations.